Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) EPS (Weighted Average and Diluted) (2018 - 2025)

Voyager Therapeutics (VYGR) has disclosed EPS (Weighted Average and Diluted) for 8 consecutive years, with -$0.47 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 21.67% to -$0.47 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.04 through Dec 2025, down 78.95% year-over-year, with the annual reading at -$2.04 for FY2025, 80.53% down from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.47 in Q4 2025 for Voyager Therapeutics, roughly flat from -$0.47 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.94 in Q1 2023 to a low of -$0.8 in Q2 2021.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.16 across 5 years, with a median of -$0.5 in 2022.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 513.33% in 2022 and later surged 625.0% in 2023.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.15 in 2021, then crashed by 513.33% to -$0.62 in 2022, then surged by 291.94% to $1.19 in 2023, then plummeted by 150.42% to -$0.6 in 2024, then increased by 21.67% to -$0.47 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for VYGR at -$0.47 in Q4 2025, -$0.47 in Q3 2025, and -$0.57 in Q2 2025.